Zhaohui Su, VP of Biostatistics at Ontada, shared a post on LinkedIn:
“Clinical research in 2026 is poised for a transformative phase characterized by increasing complexity, rapid innovation, and a heightened reliance on technology. The adoption of AI will expand, particularly in areas such as adaptive trial design and supply chain forecasting. However, uptake will be cautious due to regulatory and safety considerations.
The rise of hybrid and decentralized trials will shift the focus from whether to decentralize to how to design participant-centric studies. Additionally, the demands of precision and personalized medicine, especially in oncology, CNS, and cardiovascular diseases, will intensify operational requirements.
Sponsors and CROs that prioritize agility, integration, and predictive intelligence will secure a significant competitive advantage.
Source.”
More posts featuring Zhaohui Su.